PDF(Pubmed)
Abstract：
UNASSIGNED: Despite positive trends in SARS-CoV-2 epidemiology, seroprevalence surveys remain an important tool for estimating the magnitude of the COVID-19 pandemic. This study aimed to investigate the prevalence of IgG antibodies against SARS-CoV-2 nucleocapsid (N) and spike (S) proteins in a sample of the Lithuanian population (N = 517) and evaluate how the pattern of seropositivity correlates with the levels of SARS-CoV-2 infection and vaccination.
UNASSIGNED: Study participants (aged 18-88 years) filled in the questionnaire self-reporting their demographic-social variables, health status, and SARS-CoV-2-related status. The anti-S and anti-N IgG levels were estimated using a microarray ELISA test.
UNASSIGNED: After several pandemic waves and vaccination campaign, the seroprevalence of SARS-CoV-2-specific IgG in the analyzed sample was 97.87 % by March-May 2023. We determined the 96.91 % prevalence of anti-S and 58.03 % prevalence of anti-N IgG. The majority of study participants (71.18 %) had hybrid immunity induced by vaccination and SARS-CoV-2 infection. 20.3 % of study participants were anti-N IgG positive without reporting any previous symptoms or a positive SARS-CoV-2 test. A decline of anti-N IgG positivity within 9 months after infection was observed.
UNASSIGNED: This study demonstrates high total seroprevalence in March-May 2023 in all age groups indicating a widely established humoral immunity against SARS-CoV-2 in Lithuania.
UNASSIGNED: Study participants (aged 18-88 years) filled in the questionnaire self-reporting their demographic-social variables, health status, and SARS-CoV-2-related status. The anti-S and anti-N IgG levels were estimated using a microarray ELISA test.
UNASSIGNED: After several pandemic waves and vaccination campaign, the seroprevalence of SARS-CoV-2-specific IgG in the analyzed sample was 97.87 % by March-May 2023. We determined the 96.91 % prevalence of anti-S and 58.03 % prevalence of anti-N IgG. The majority of study participants (71.18 %) had hybrid immunity induced by vaccination and SARS-CoV-2 infection. 20.3 % of study participants were anti-N IgG positive without reporting any previous symptoms or a positive SARS-CoV-2 test. A decline of anti-N IgG positivity within 9 months after infection was observed.
UNASSIGNED: This study demonstrates high total seroprevalence in March-May 2023 in all age groups indicating a widely established humoral immunity against SARS-CoV-2 in Lithuania.
摘要：
■尽管SARS-CoV-2流行病学呈积极趋势，血清阳性率调查仍然是估计COVID-19大流行程度的重要工具。本研究旨在调查立陶宛人群（N=517）中针对SARS-CoV-2核衣壳（N）和刺突（S）蛋白的IgG抗体的流行情况，并评估血清阳性模式与SARS-CoV-2感染和疫苗接种的水平。
■研究参与者（18-88岁）填写了自我报告的人口-社会变量的问卷，健康状况,和SARS-CoV-2相关状态。使用微阵列ELISA测试估计抗S和抗NIgG水平。
■在几次大流行浪潮和疫苗接种运动之后，截至2023年3月-5月,分析样本中SARS-CoV-2特异性IgG的血清阳性率为97.87%.我们确定了96.91％的抗S患病率和58.03％的抗NIgG患病率。大多数研究参与者（71.18％）具有由疫苗接种和SARS-CoV-2感染诱导的混合免疫。20.3％的研究参与者抗NIgG阳性，未报告任何先前症状或SARS-CoV-2测试阳性。观察到感染后9个月内抗NIgG阳性下降。
■这项研究表明，2023年3月至5月，所有年龄段的血清总阳性率都很高，表明立陶宛对SARS-CoV-2的体液免疫已得到广泛建立。
■研究参与者（18-88岁）填写了自我报告的人口-社会变量的问卷，健康状况,和SARS-CoV-2相关状态。使用微阵列ELISA测试估计抗S和抗NIgG水平。
■在几次大流行浪潮和疫苗接种运动之后，截至2023年3月-5月,分析样本中SARS-CoV-2特异性IgG的血清阳性率为97.87%.我们确定了96.91％的抗S患病率和58.03％的抗NIgG患病率。大多数研究参与者（71.18％）具有由疫苗接种和SARS-CoV-2感染诱导的混合免疫。20.3％的研究参与者抗NIgG阳性，未报告任何先前症状或SARS-CoV-2测试阳性。观察到感染后9个月内抗NIgG阳性下降。
■这项研究表明，2023年3月至5月，所有年龄段的血清总阳性率都很高，表明立陶宛对SARS-CoV-2的体液免疫已得到广泛建立。
